Hypoxia-regulated gene expression and prognosis in loco-regional gastroesophageal cancer

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1327-1335

  Winther, Mette ^a   Alsner, Jan ^a   Tramm, Trine ^a   Nordsmark, Marianne ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; CAPECITABINE; EPIRUBICIN; FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; DISEASE SPECIFIC SURVIVAL; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTROESOPHAGEAL CANCER; GENE EXPRESSION PROFILING; HUMAN TISSUE; INDEPENDENT VARIABLE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PH; SURVIVAL RATE; TREND STUDY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; ANOXIA; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884582327     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.818247     Document Type: Article

References (32)

1. Pennathur A, Gibson MK, Jobe B A, Luketich J D. O esophageal carcinoma. Lancet 2013;381:400-12
2. Hartgrink HH, Jansen EP, vaNgrieken NC, van de Velde CJ. Gastric cancer. Lancet 2009;374:477-90
3. Vallbohmer D, Brabender J, Metzger R, Holscher A H. Genetics in the pathogenesis of esophageal cancer: Possible predictive and prognostic factors. J Gastrointest Surg 2010;14(SUPPL. 1):S75-80
4. Wu X, Hedman H, Bergqvist M, Bergstrom S, Henriksson R, Gullbo J, et al. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncol 2012;51:69-76
5. Pennathur A, Xi L, Litle VR, Gooding WE, Krasinskas A, Landreneau RJ, et al. Gene expression profi les in esophageal adenocarcinoma predict survival after resection. J Thorac Cardiovasc Surg 2013;145:505-12; discussion 512-3
6. Stiekema J, Boot H, Aleman BM, Wessels L F, van Sandick JW. Prognostication and prediction using gene expression profi ling in oesophageal cancer. Eur J Surg Oncol 2013;39:17-23
7. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47
8. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24
9. Vaupel P, Mayer A. Hypoxia in cancer: Signifi cance anDimpact on clinicaLoutcome. Cancer Metastasis Rev 2007;26:225-39
10. Harrison L, Blackwell K. Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004;9(Suppl5):31-40
11. Vaupel P, Mayer A. Hypoxia in cancer: Signifi cance anDimpact on clinicaLoutcome. Cancer Metastasis Rev 2007;26:225-39
12. Overgaard J. Hypoxic modifi cation of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32
13. Mortensen L S, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14-20
14. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective triaLof hypoxiaspecifi c PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21-8
15. Tran LB, Bol A, Labar D, Jordan B, Magat J, Mignion L, et al. Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: A comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiother Oncol 2012;105:29-35
16. Mortensen L S, Busk M, Nordsmark M, Jakobsen S, Theil J, Overgaard J, et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: A preclinical study. Radiother Oncol 2011;99:418-23
17. Shen Z, Kauttu T, Seppanen H, Vainionpaa S, Ye Y, Wang S, et al. Both macrophages and hypoxia play critical role in regulating invasion of gastric cancer in vitro. Acta Oncol 2013;52:852-60
18. BuffAfM, Harris AL, West CM, Miller CJ. Large metaanalysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010;102:428-35
19. Winter S C, BuffAf M, Silva P, Miller C, Valentine H R, Turley H, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007;67:3441-9
20. Halle C, Andersen E, Lando M, Aarnes E K, Hasvold G, Holden M, et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrastenhanced MRI. Cancer Res 2012;72:5285-95
21. Toustrup K, Sorensen B S, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifi er with predictive impact for hypoxic modifi cation of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923-31
22. Toustrup K, Sorensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J, et al. Gene expression classifi er predicts for hypoxic modifi cation of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012;102:122-9
23. Sorensen BS, Toustrup K, Horsman MR, Overgaard J, Alsner J. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. Acta Oncol 2010;49:895-905
24. Toustrup K, Sorensen B S, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012;22:119-27
25. Starmans MH, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, et al. The prognostic value of temporaLin vitro anDin vivo derived hypoxia gene-expression signatures in breast cancer. Radiother Oncol 2012;102:436-43
26. Matsuyama T, Nakanishi K, Hayashi T, Yoshizumi Y, Aiko S, Sugiura Y, et al. Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci 2005;96:176-82
27. Tanaka N, KatOh, Inose T, Kimura H, Faried A, Sohda M, et al. Expression of carbonic anhydrase 9, apotentiaLintrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2008;99:1468-75
28. Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007;9:1237-94
29. Gebski V, Burmeister B, Smithers B M, Foo K, Zalcberg J, Simes J, et al. Survival benefi ts from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007;8:226-34
30. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
31. Courrech StaaLeF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW. Systematic review of the benefi ts and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010;97:1482-96
32. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 2005;6:659-68